Gynecological cancers in patients with inflammatory rheumatic diseases

被引：0

作者：

Schmalzing, M. ^{[1
]}

Krockenberger, M. ^{[2
]}

Honig, A. ^{[3
]}

Tony, H. -P. ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Rheumatol Klin Immunol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany

[2] Univ Klinikum Wurzburg, Frauenklin & Poliklin, Wurzburg, Germany

[3] Kathol Klinikum Mainz, Klin Frauenheilkunde & Geburtshilfe, Mainz, Germany

来源：

ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 01期

关键词：

Immunosuppression; Breast cancer; Ovarian cancer; Cervical cancer; Systemic lupus erythematosus; BREAST-CANCER; FOLLOW-UP; INTRAEPITHELIAL NEOPLASIA; THERAPY; RISK; ARTHRITIS; WOMEN; METAANALYSIS; DIAGNOSIS; SURVIVAL;

D O I：

10.1007/s00393-016-0044-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of gynecological cancers in patients with inflammatory rheumatic diseases only seems to be elevated with respect to cervical cancer and mainly in patients with systemic lupus erythematosus. There is increasing evidence for an influence of the immune system on tumor control of gynecological malignancies; however, an adverse influence of immunosuppressive treatment in rheumatic patients was indicated only for the risk of cervical cancer. In contrast, biologics could not be shown to cause an increased risk of cervical cancer but data on this topic are limited. General screening recommendations exist for breast cancer and cervical cancer. Recommendations for follow-up after oncological treatment are presented. Because of limited evidence immunosuppressive and biological treatment should be applied with great restraint at least within the first 5 years after curative oncological treatment also for gynecological tumors. As far as breast cancer is concerned an even longer interval is under discussion.

引用

页码：63 / 67

页数：5

共 50 条

[21] Gynecological manifestations in the course of rheumatic diseases
Jordan Arias, Jacqueline Alexandra
Saltos Salazar, Adita Cristina
Chimborazo Cambo, Amada Catalina
Moreno Garcia, Katherine Silvana
Sancho Perez, Paulina Elizabeth
REVISTA CUBANA DE REUMATOLOGIA, 2022, 24 (02):
[22] Inflammatory rheumatic diseases in the elderly
Wollenhaupt, J.
INTERNIST, 2012, 53 (09): : 1020 - +
[23] Environmental (nongenetic) factors in gynecological cancers: update and future perspectives
Webb, Penelope M.
FUTURE ONCOLOGY, 2015, 11 (02) : 295 - 307
[24] Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases
Buehler, Silja
Eperon, Gilles
Ribi, Camillo
Kyburz, Diego
van Gompel, Fons
Visser, Leo G.
Siegrist, Claire-Anne
Hatz, Christoph
SWISS MEDICAL WEEKLY, 2015, 145
[25] Suspected inflammatory rheumatic diseases in patients presenting with skin rashes
Alves, Francisca
Goncalo, Margarida
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2019, 33 (04):
[26] Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw
Schwaneck, E. C.
Streit, A.
Krone, M.
Hartmann, S.
Mueller-Richter, U.
Kuebler, A. C.
Gadeholt, O.
Schmalzing, M.
Tony, H. -P.
Brands, R. C.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (02): : 203 - 209
[27] Management of Gynecological Cancers During Pregnancy
Han, Sileny N.
Verheecke, Magali
Vandenbroucke, Tineke
Gziri, Mina Mhallem
Van Calsteren, Kristel
Amant, Frederic
CURRENT ONCOLOGY REPORTS, 2014, 16 (12)
[28] Frequent Infections in Patients with Inflammatory Rheumatic Diseases
Ehrenstein, B.
AKTUELLE RHEUMATOLOGIE, 2014, 39 (03) : 170 - 174
[29] Vaccination of patients with autoimmune inflammatory rheumatic diseases
Westra, Johanna
Rondaan, Christien
van Assen, Sander
Bijl, Marc
NATURE REVIEWS RHEUMATOLOGY, 2015, 11 (03) : 135 - 145
[30] Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer
Yadav, Budhi Singh
Sharma, Suresh C.
Patel, Firuza D.
Rai, Bhavana
Ghoshal, Sushmita
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (06) : 1298 - 1304

← 1 2 3 4 5 →